© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
June 11, 2022
Results of the phase 3 RATIONALE-309 trial demonstrate efficacy of tislelizumab added to chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.
June 07, 2022
HPV-targeting immunotherapeutic PDS0101 in combination pembrolizumab may represent a new option for patients with HPV-positive recurrent or metastatic head and neck squamous cell carcinoma.
Treatment with zanubrutinib and obinutuzumab improved outcomes in patients with relapsed/refractory follicular lymphoma vs obinutuzumab monotherapy.
June 06, 2022
BRAF V600 mutation–positive pediatric low-grade glioma positively responds to combination treatment with dabrafenib plus trametinib, according to data presented at 2022 ASCO.
Subgroup analysis of the RE-MIND trial support use of tafasitamab plus lenalidomide to treat high-risk diffuse large B-cell lymphoma.
January 07, 2022
Investigators believe that storing red blood cells in a hypoxic state could reduce the development of vaso-occlusion flowing transfusion.
December 14, 2021
The combination of high-frequency and low-dose acalabrutinib and rituximab demonstrated a 100% overall response rate in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
December 13, 2021
Glofitamab monotherapy or in combination with obinutuzumab led to strong response rates for patients with multiple relapsed or refractory follicular lymphoma.
December 12, 2021
A strong antibody response was seen in patients with acute myeloid leukemia and myelodysplastic syndrome who received the mRNA COVID-19 vaccine.
September 21, 2021
According to results from the Blood First Assay Screening Trial, blood-based tumor mutational burden did not predict a benefit of atezolizumab over chemotherapy for patients with non-small cell lung cancer.